These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 12652461)
1. Immunochemotherapy: the new standard in aggressive non-Hodgkin's lymphoma in the elderly. Coiffier B Semin Oncol; 2003 Feb; 30(1 Suppl 2):21-7. PubMed ID: 12652461 [TBL] [Abstract][Full Text] [Related]
2. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Plosker GL; Figgitt DP Drugs; 2003; 63(8):803-43. PubMed ID: 12662126 [TBL] [Abstract][Full Text] [Related]
3. Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma. Coiffier B Semin Oncol; 2002 Apr; 29(2 Suppl 6):18-22. PubMed ID: 12040530 [TBL] [Abstract][Full Text] [Related]
4. The therapeutic use of rituximab in non-Hodgkin's lymphoma. Marcus R; Hagenbeek A Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982 [TBL] [Abstract][Full Text] [Related]
6. Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. Vose JM; Link BK; Grossbard ML; Czuczman M; Grillo-Lopez A; Fisher RI Leuk Lymphoma; 2005 Nov; 46(11):1569-73. PubMed ID: 16236611 [TBL] [Abstract][Full Text] [Related]
8. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Keating GM Drugs; 2010 Jul; 70(11):1445-76. PubMed ID: 20614951 [TBL] [Abstract][Full Text] [Related]
10. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. Vose JM; Link BK; Grossbard ML; Czuczman M; Grillo-Lopez A; Gilman P; Lowe A; Kunkel LA; Fisher RI J Clin Oncol; 2001 Jan; 19(2):389-97. PubMed ID: 11208830 [TBL] [Abstract][Full Text] [Related]
11. Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma. Intragumtornchai T; Bunworasate U; Nakorn TN; Rojnuckarin P Leuk Lymphoma; 2006 Jul; 47(7):1306-14. PubMed ID: 16923561 [TBL] [Abstract][Full Text] [Related]
12. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Wunderlich A; Kloess M; Reiser M; Rudolph C; Truemper L; Bittner S; Schmalenberg H; Schmits R; Pfreundschuh M; Loeffler M; Ann Oncol; 2003 Jun; 14(6):881-93. PubMed ID: 12796026 [TBL] [Abstract][Full Text] [Related]
13. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Boye J; Elter T; Engert A Ann Oncol; 2003 Apr; 14(4):520-35. PubMed ID: 12649096 [TBL] [Abstract][Full Text] [Related]
14. [Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China--a multi-center randomized trail]. Lin TY; Zhang HY; Huang Y; Guan ZZ; Shen T; Shi YK; Zhu J; Ke XY; Wang HQ; Shen ZX; Yu SY; Liu T; Shi XL Ai Zheng; 2005 Dec; 24(12):1421-6. PubMed ID: 16351785 [TBL] [Abstract][Full Text] [Related]
15. Diffuse aggressive lymphoma. Fisher RI; Miller TP; O'Connor OA Hematology Am Soc Hematol Educ Program; 2004; ():221-36. PubMed ID: 15561685 [TBL] [Abstract][Full Text] [Related]
16. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202 [TBL] [Abstract][Full Text] [Related]
17. [Clinical analysis of rituximab combined with chemotherapy in treating aggressive B-cell non-Hodgkin's lymphoma]. Zhang HY; Lin TY; Jiang WQ; Zhang L; Huang HQ; Xia ZJ; Sun XF; He YJ; Guan ZZ Ai Zheng; 2004 Dec; 23(12):1681-6. PubMed ID: 15601560 [TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of the addition of rituximab to CHOP in young patients with good-prognosis diffuse large-B-cell lymphoma. Ferrara F; Ravasio R Clin Drug Investig; 2008; 28(1):55-65. PubMed ID: 18081361 [TBL] [Abstract][Full Text] [Related]
19. Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma. Coiffier B Tumori; 2002; 88(1 Suppl 1):S26-8. PubMed ID: 11989916 [No Abstract] [Full Text] [Related]
20. Treatment of aggressive non-Hodgkin's lymphoma: a north American perspective. Sehn LH; Connors JM Oncology (Williston Park); 2005 Apr; 19(4 Suppl 1):26-34. PubMed ID: 15934515 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]